Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  
  • Home
  • Views On News
  • Jul 2, 2021 - Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary

Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary

Jul 2, 2021

Shares of Aurobindo Pharma gained over 4% on the BSE in intra-day trade today.

The pharmaceutical firm said it would sell its generic injectables and ophthalmics manufacturing unit to Eugia Pharma Specialities, a wholly-owned subsidiary of the company.

The transfer of the business undertaking will be done for a lump-sum consideration of Rs 8.8 bn.

The proposed transaction is subject to regulatory approvals in the US and Europe. It's estimated to be completed by September 2022.

Consolidation of injectables business on cards

As per analysts, Aurobindo has US$ 400 m of generic injectables and US$ 95 m of oncology branded injectables that together account for 14% of the company's revenue.

The company has been looking to consolidate its injectable business under one roof as evident from the transfer of other injectable units such as Auronext (November 2020), Unit-16 (May 2021), and AuroCure (May 2021).

--- Advertisement ---
Replay Available: The EV Gold Rush

Get the details of 3 EV stocks to potentially make life-changing gains in the long term

Catch a FREE REPLAY Here

Thus, the transfer of the business unit to Eugia is on expected lines and brings Aurobindo one step closer to potentially carve out an injectable entity.

The independent entity, with all the injectable assets consolidated under it, would enable the pursuit of growth opportunities with a self-sustaining capital structure.

It would also provide flexibility for value creation opportunities including exploration of alliances with focused partners in the injectables business.

In an exchange filing, Aurobindo Pharma said,

  • Due to the specialisation of this business and to bring greater focus and attention, the company is carving out the unit to Eugia Pharma Specialities.

    The proposed slump sale will improve operational efficiency by creating a lean, competitive organisation with a focus on faster decision making for expedited growth, with a dedicated management team.

Eugia is engaged in research and manufacturing in the oncology and hormone segment.

The generic injectables and ophthalmics unit reported a revenue of Rs 9.3 bn in the financial year 2021, contributing 5.9% of the standalone revenue of Aurobindo Pharma.

--- Advertisement ---
[Alert] Sell These 3 Stocks Immediately

These 3 stocks are ticking time bombs in your portfolio.

It is very likely that you could be owning these 3 overvalued...

fundamentally weak... ready to crash stocks... in your portfolio today.

Because many stock brokers have painted rosy pictures of these stocks. But the reality is starkly different.

If the market crashes, then these stocks could wipe out your wealth.

You should get rid of these stocks as soon as possible.

Click her for full details of these 3 landmines

Formulations unit deal value raised

Aurobindo Pharma also increased the amount it will receive for transferring its oral formulations manufacturing business to another fully owned subsidiary.

In its meeting on 27 February, the board proposed to transfer the business to APL Healthcare on a slump-sale basis at Rs 10.9 bn based on financial statements as of December 2020.

On 1 July, it raised the deal value to Rs 13.2 bn after adjusting for differences from 1 January to the closing date of the transaction.

How the stock markets reacted to the news

Shares of Aurobindo Pharma opened at Rs 979.8 on the NSE and Rs 984.9 on the BSE today and rallied over 4%.

The stock has gained over 9% year-to-date compared to the 12% rise in benchmark indices.

The scrip touched its 52-week high of Rs 1063.8 on 11 May 2021. It had touched its 52-week low of Rs 737.9 on 24 September 2020.

At its current price, it is trading at a P/E ratio of 18.1.

About Aurobindo Pharma

Aurobindo Pharma is a pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India.

The company manufactures generic pharmaceuticals and active pharmaceutical ingredients.

The company's area of activity includes six major therapeutic/product areas - antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterological, and anti-allergics.

Watch Now: A Massive 15x Opportunity in Electric Vehicles

Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues.

The company exports to over 125 countries with more than 70% of its revenues derived out of international operations. Its marketing partners include AstraZeneca and Pfizer.

For more details about the company, you can have a look at Aurobindo Pharma's factsheet and Aurobindo Pharma's quarterly results on our website.

You can also compare Aurobindo Pharma with its peers.

Aurobindo Pharma vs Ajanta Pharma

Aurobindo Pharma vs Sun Pharmaceuticals

Aurobindo Pharma vs Cipla

Aurobindo Pharma vs Abbott India

Aurobindo Pharma vs Biocon

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...

Ayesha Shetty

Ayesha Shetty is a financial writer with the StockSelect team at Equitymaster. An engineer by qualification, she uses her analytical skills to decode the latest developments in financial markets. This reflects in her well-researched and insightful articles. When she is not busy separating financial fact from fiction, she can be found reading about new trends in technology and international politics.

Equitymaster requests your view! Post a comment on "Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary". Click here!


More Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 2.0% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (down 2.0% YoY). Sales on the other hand came in at Rs 57 bn (down 3.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

Here's an analysis of the annual report of AUROBINDO PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

Aurobindo Pharma's Stock Falls After Profits Decline 7% (Views On News)

Jun 1, 2021

Aurobindo Pharma shares fell nearly 4% after quarterly earnings disappoint.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

More Views on News

Most Popular

All You Need to Know About Primary and Secondary Markets

A look at the various types of primary and secondary markets and the key differences between them.

5 Green Energy Stocks to Watch as India Readies for a Revolution (Views On News)

Oct 13, 2021

The excitement around green energy stocks has opened up a huge contrarian opportunity in the traditional energy space.

Could HDFC Bank be a Big EV Winner? The Answer Will Surprise You... (Profit Hunter)

Oct 13, 2021

Why should investors take it for granted that India's Tesla will be one of the major auto stocks?

Tata Group Stocks are on Fire: Which one Should You Buy? (Profit Hunter)

Oct 15, 2021

Tata group stocks are on fire. Find out which one deserves your attention.

Massive Surge in the Shares of Tata Motors Today. Key Factors Favouring the Rally (Views On News)

Oct 13, 2021

Tata Motors zooms 23% after report of TPG investing Rs 75 bn in EV arm.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Oct 25, 2021 (Close)


  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks